Accelerating precision medicine in metastatic prostate cancer

Joaquin Mateo; Rana McKay; Wassim Abida; Rahul Aggarwal; Joshi Alumkal; Ajjai Alva; Felix Feng; Xin Gao; Julie Graff; Maha Hussain; Fatima Karzai; Bruce Montgomery; William Oh; Vaibhav Patel; Dana Rathkopf; Matthew Rettig; Nikolaus Schultz; Matthew Smith; David Solit; Cora Sternberg; Eliezer Van Allen; David VanderWeele; Jake Vinson; Howard R. Soule; Arul Chinnaiyan; Eric Small; Jonathan W. Simons; William Dahut; Andrea K. Miyahira; Himisha Beltran

doi:10.1038/s43018-020-00141-0

Accelerating precision medicine in metastatic prostate cancer

Joaquin Mateo, Rana McKay, Wassim Abida, Rahul Aggarwal, Joshi Alumkal, Ajjai Alva, Felix Feng, Xin Gao, Julie Graff, Maha Hussain, Fatima Karzai, Bruce Montgomery, William Oh, Vaibhav Patel, Dana Rathkopf, Matthew Rettig, Nikolaus Schultz, Matthew Smith, David Solit, Cora SternbergEliezer Van Allen, David VanderWeele, Jake Vinson, Howard R. Soule, Arul Chinnaiyan, Eric Small, Jonathan W. Simons, William Dahut, Andrea K. Miyahira, Himisha Beltran^*

^*Corresponding author for this work

Medicine, Hematology Oncology Division

Research output: Contribution to journal › Article › peer-review

58 Scopus citations

Abstract

Despite advances in the screening and treatment of prostate cancer, the therapy options available, particularly for later stages of the disease, remain limited, and the treatment-resistant setting represents a serious unmet medical need. Moreover, disease heterogeneity and disparities in patient access to medical advances result in considerable variability in outcomes across patients. Disease classification based on genomic sequencing is a promising approach for identifying patients whose tumors exhibit actionable targets and for making more informed treatment decisions. Here we discuss how precision oncology can be accelerated to inform broader genomically driven clinical decisions for men with advanced prostate cancer, to inform drug development and, ultimately, to contribute to new treatment paradigms.

Original language	English (US)
Pages (from-to)	1041-1053
Number of pages	13
Journal	Nature Cancer
Volume	1
Issue number	11
DOIs	https://doi.org/10.1038/s43018-020-00141-0
State	Published - Nov 2020

Funding

J.M. reports advisory board participation for Amgen, AstraZeneca, Roche, Janssen, MSD and Clovis Oncology; and research funding from AstraZeneca and Pfizer Oncology. R.M. received research funding from Bayer, Pfizer and Tempus; serves on advisory board for Bayer, Bristol Myers Squib, Exelixis, Janssen, Novartis, Pfizer, Sanofi and Tempus; and is a consultant for Dendreon and Vividion. W.A. reports consulting/advisory for Clovis, Janssen, More Health, ORIC and Daiichi Sankyo; research funding from AstraZeneca, Zenith Epigenetics, Clovis, GlaxoSmithKline, ORIC and Epizyme; travel from GlaxoSmithKline, Clovis and ORIC; and honoraria from CARET. R.A. reports advisory board participation and research funding from Merck, AstraZeneca and Janssen. B.M. reports research funding from AstraZeneca, Janssen, Clovis, Astellas and Beigene. M.R. reports consulting for Amgen, Ambryx and Constellation; educational writing and consulting for Plexus; speaking for Bayer and Janssen; and funding and clinical research support from Novartis, Astellas, Medivation and Merck. D.S. has consulted for/received honoraria from Pfizer, Loxo Oncology, Lilly Oncology, BioBridge, Vivideon Therapeutics and Illumina. E.V.A. reports advisory/consulting from Tango Therapeutics, Genome Medical, Invitae, Enara Bio, Janssen, Manifold Bio and Monte Rosa; research support from Novartis and BMS; equity in Tango Therapeutics, Genome Medical, Syapse, Enara Bio, Manifold Bio, Microsoft and Monte Rosa; travel reimbursement from Roche/ Genentech; and institutional patents on chromatin mutations and immunotherapy response, and methods for clinical interpretation. D.V. reports honoraria from Clovis Oncology. H.B. reports advisory/consulting from Janssen, Amgen, Astra Zeneca, Pfizer, Astellas and Sanofi Genzyme; and research funding from Janssen, Abbvie Stemcentryx, Eli Lilly, Millenium and Astellas. J.V. is employed by the Prostate Cancer Clinical Trials Consortium. H.R.S., J.W.S. and A.K.M. are employed by the Prostate Cancer Foundation.

ASJC Scopus subject areas

Oncology
Cancer Research

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/s43018-020-00141-0

Cite this

Mateo, J., McKay, R., Abida, W., Aggarwal, R., Alumkal, J., Alva, A., Feng, F., Gao, X., Graff, J., Hussain, M., Karzai, F., Montgomery, B., Oh, W., Patel, V., Rathkopf, D., Rettig, M., Schultz, N., Smith, M., Solit, D., ... Beltran, H. (2020). Accelerating precision medicine in metastatic prostate cancer. Nature Cancer, 1(11), 1041-1053. https://doi.org/10.1038/s43018-020-00141-0

@article{eb1da7d24b9d485e8f4705d371779360,

title = "Accelerating precision medicine in metastatic prostate cancer",

abstract = "Despite advances in the screening and treatment of prostate cancer, the therapy options available, particularly for later stages of the disease, remain limited, and the treatment-resistant setting represents a serious unmet medical need. Moreover, disease heterogeneity and disparities in patient access to medical advances result in considerable variability in outcomes across patients. Disease classification based on genomic sequencing is a promising approach for identifying patients whose tumors exhibit actionable targets and for making more informed treatment decisions. Here we discuss how precision oncology can be accelerated to inform broader genomically driven clinical decisions for men with advanced prostate cancer, to inform drug development and, ultimately, to contribute to new treatment paradigms.",

author = "Joaquin Mateo and Rana McKay and Wassim Abida and Rahul Aggarwal and Joshi Alumkal and Ajjai Alva and Felix Feng and Xin Gao and Julie Graff and Maha Hussain and Fatima Karzai and Bruce Montgomery and William Oh and Vaibhav Patel and Dana Rathkopf and Matthew Rettig and Nikolaus Schultz and Matthew Smith and David Solit and Cora Sternberg and \{Van Allen\}, Eliezer and David VanderWeele and Jake Vinson and Soule, \{Howard R.\} and Arul Chinnaiyan and Eric Small and Simons, \{Jonathan W.\} and William Dahut and Miyahira, \{Andrea K.\} and Himisha Beltran",

note = "Publisher Copyright: {\textcopyright} 2020, Springer Nature America, Inc. part of Springer Nature.",

year = "2020",

month = nov,

doi = "10.1038/s43018-020-00141-0",

language = "English (US)",

volume = "1",

pages = "1041--1053",

journal = "Nature Cancer",

issn = "2662-1347",

publisher = "Nature Research",

number = "11",

}

Mateo, J, McKay, R, Abida, W, Aggarwal, R, Alumkal, J, Alva, A, Feng, F, Gao, X, Graff, J, Hussain, M, Karzai, F, Montgomery, B, Oh, W, Patel, V, Rathkopf, D, Rettig, M, Schultz, N, Smith, M, Solit, D, Sternberg, C, Van Allen, E, VanderWeele, D, Vinson, J, Soule, HR, Chinnaiyan, A, Small, E, Simons, JW, Dahut, W, Miyahira, AK & Beltran, H 2020, 'Accelerating precision medicine in metastatic prostate cancer', Nature Cancer, vol. 1, no. 11, pp. 1041-1053. https://doi.org/10.1038/s43018-020-00141-0

TY - JOUR

T1 - Accelerating precision medicine in metastatic prostate cancer

AU - Mateo, Joaquin

AU - McKay, Rana

AU - Abida, Wassim

AU - Aggarwal, Rahul

AU - Alumkal, Joshi

AU - Alva, Ajjai

AU - Feng, Felix

AU - Gao, Xin

AU - Graff, Julie

AU - Hussain, Maha

AU - Karzai, Fatima

AU - Montgomery, Bruce

AU - Oh, William

AU - Patel, Vaibhav

AU - Rathkopf, Dana

AU - Rettig, Matthew

AU - Schultz, Nikolaus

AU - Smith, Matthew

AU - Solit, David

AU - Sternberg, Cora

AU - Van Allen, Eliezer

AU - VanderWeele, David

AU - Vinson, Jake

AU - Soule, Howard R.

AU - Chinnaiyan, Arul

AU - Small, Eric

AU - Simons, Jonathan W.

AU - Dahut, William

AU - Miyahira, Andrea K.

AU - Beltran, Himisha

PY - 2020/11

Y1 - 2020/11

N2 - Despite advances in the screening and treatment of prostate cancer, the therapy options available, particularly for later stages of the disease, remain limited, and the treatment-resistant setting represents a serious unmet medical need. Moreover, disease heterogeneity and disparities in patient access to medical advances result in considerable variability in outcomes across patients. Disease classification based on genomic sequencing is a promising approach for identifying patients whose tumors exhibit actionable targets and for making more informed treatment decisions. Here we discuss how precision oncology can be accelerated to inform broader genomically driven clinical decisions for men with advanced prostate cancer, to inform drug development and, ultimately, to contribute to new treatment paradigms.

AB - Despite advances in the screening and treatment of prostate cancer, the therapy options available, particularly for later stages of the disease, remain limited, and the treatment-resistant setting represents a serious unmet medical need. Moreover, disease heterogeneity and disparities in patient access to medical advances result in considerable variability in outcomes across patients. Disease classification based on genomic sequencing is a promising approach for identifying patients whose tumors exhibit actionable targets and for making more informed treatment decisions. Here we discuss how precision oncology can be accelerated to inform broader genomically driven clinical decisions for men with advanced prostate cancer, to inform drug development and, ultimately, to contribute to new treatment paradigms.

UR - http://www.scopus.com/inward/record.url?scp=85096141661&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85096141661&partnerID=8YFLogxK

U2 - 10.1038/s43018-020-00141-0

DO - 10.1038/s43018-020-00141-0

M3 - Article

C2 - 34258585

AN - SCOPUS:85096141661

SN - 2662-1347

VL - 1

SP - 1041

EP - 1053

JO - Nature Cancer

JF - Nature Cancer

IS - 11

ER -

Accelerating precision medicine in metastatic prostate cancer

Abstract

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this